Long-term effects of weight-reducing drugs in hypertensive patients

Cochrane Database of Systematic Reviews

Volumn , Issue 3, 2009, Pages

  Siebenhofer, Andrea ^a   Horvath, Karl ^a   Jeitler, Klaus ^a   Berghold, Andrea ^a   Stich, Anne K ^b   Matyas, Eva ^a   Pignitter, Nicole ^a   Siering, Ulrich ^b  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

^b INSTITUTE FOR QUALITY AND EFFICIENCY IN HEALTH CARE IQWIG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; RIMONABANT; SIBUTRAMINE; TETRAHYDROLIPSTATIN;

BODY WEIGHT; DIASTOLIC BLOOD PRESSURE; DIET; DRUG EFFECT; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERTENSION; INCIDENCE; MORBIDITY; MORTALITY; OUTCOME ASSESSMENT; PUBLISHING; REVIEW; SYSTOLIC BLOOD PRESSURE; WEIGHT REDUCTION;

EID: 70049114002     PISSN: 1469493X     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD007654.pub2     Document Type: Review

References (85)

1. Bakris G, Calhoun D, Egan B, Hellmann C, Dolker M, Kingma I, et al.Orlistat improves blood pressure control in obese subjects with treated but inadequately controlled hypertension. Journal of Hypertension 2002;20(11):2257-2267 (Pubitemid 35388245)
2. Cocco G, Pandolfi S, Rousson V. Sufficient weight reduction decreases cardiovascular complications in diabetic patients with the metabolic syndrome: A randomized study of orlistat as an adjunct to lifestyle changes (diet and exercise). Heart Drug 2005;5(2):68-74. (Pubitemid 40522785)
3. Fanghaenel G, Cortinas L, Sanchez-Reyes L, Gomez-Santos R, Campos-Franco E, Berber A. Safety and efficacy of sibutramine in overweight Hispanic patients with hypertension. Advances in Therapy 2003;20(2):101-113 (Pubitemid 36667540)
4. Faria AN, Ribeiro Filho FF, Kohlmann NE, Gouvea F, Sr, Zanella MT. Effects of sibutramine on abdominal fat mass, insulin resistance and blood pressure in obese hypertensive patients. Diabetes, Obesity & Metabolism 2005;7(3):246-253
5. * Faria AN, Ribeiro Filho FF, Lerario DDG, Kohlmann N, Gouvea Ferreira SR, Zanella MT. Effects of sibutramine on the treatment of obesity in patients with arterial hypertension. Portuguese, English]. Arquivos Brasileiros de Cardiologia 2002;78(2):172-180
6. Guy-Grand B, Drouin P, Eschwege E, Gin H, Joubert JM, Valensi P. Effects of orlistat on obesity-related diseases - a six-month randomized trial. Diabetes, Obesity & Metabolism 2004;6(5):375-383 (Pubitemid 39172860)
7. McMahon FG, Fujioka K, Singh BN, Mendel CM, Rowe E, Rolston K, et al.Efficacy and safety of sibutramine in obese white and African American patients with hypertension: a 1-year, double-blind, placebo-controlled, multicenter trial. Archives of Internal Medicine 2000;160(14):2185-2191 (Pubitemid 30482726)
8. McMahon FG, Weinstein SP, Rowe E, Ernst KR, Johnson F, Fujioka K, et al.Sibutramine is safe and effective for weight loss in obese patients whose hypertension is well controlled with angiotensin-converting enzyme inhibitors. Journal of Human Hypertension 2002;16(1):5-11. (Pubitemid 34134088)
9. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG). Evaluation of the benefits and harms of non-drug weight-reducing treatment strategies in patients with essential hypertension [Nutzenbewertung nichtmedikamentöser Behandlungsstrategien bei Patienten mit Bluthochdruck: A-Gewichtsreduktion]. http://iqwig.de/download/A05-21A- Abschlussbericht-Gewichtsreduktion-bei-Bluthochdruck-neu.pdf. Köln: Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG), 2006:19-119.
10. Torgerson JS, Arlinger K, Kappi M, Sjostrom L. Principles for enhanced recruitment of subjects in a large clinical trial. the XENDOS (XENical in the prevention of Diabetes in Obese Subjects) study experience. Controlled Clinical Trials 2001;22(5):515-525
11. Torgerson JS, Hauptman J, Boldrin MN, Sjostrom L. XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes care 2004;27(1):155-161 (Pubitemid 38196725)
12. Bach DS, Rissanen AM, Mendel CM, Shepherd G, Weinstein SP, Kelly F, et al.Absence of cardiac valve dysfunction in obese patients treated with sibutramine. Obesity Research 1999;7(4):363-369 (Pubitemid 129710597)
13. Bray GA, Blackburn GL, Ferguson JM, Greenway FL, Jain AK, Mendel CM, et al.Sibutramine produces dose-related weight loss. Obesity Research 1999;7(2):189-198
14. Broom I, Wilding J, Stott P, Myers N, UK Multimorbidity Study Group. Randomised trial of the effect of orlistat on body weight and cardiovascular disease risk profile in obese patients: UK Multimorbidity Study. International Journal of Clinical Practice 2002;56(7):494-499 (Pubitemid 35049828)
15. Davidson MH, Hauptman J, DiGirolamo M, Foreyt JP, Halsted CH, Heber D, et al.Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial.see comment]erratum appears in JAMA 1999 Apr 7;281(13):1174]. JAMA 1999;281(3):235-242 (Pubitemid 29058112)
16. Derosa G, Mugellini A, Ciccarelli L, Fogari R. Randomized, double-blind, placebo-controlled comparison of the action of orlistat, fluvastatin, or both an anthropometric measurements, blood pressure, and lipid profile in obese patients with hypercholesterolemia prescribed a standardized diet. Clinical Therapeutics 2003;25(4):1107-1122 (Pubitemid 36532581)
17. Derosa G, D'Angelo A, Salvadeo SA, Ferrari I, Gravina A, Fogari E, et al.Sibutramine effect on metabolic control of obese patients with type 2 diabetes mellitus treated with pioglitazone. Metabolism: Clinical & Experimental 2008;57(11):1552-1557
18. Despres J-P, Golay A, Sjostrom L. Effects of rimonabant onmetabolic risk factors in overweight patients with dyslipidemia. New England Journal of Medicine 2005;353(20):2121-2134 (Pubitemid 41653104)
19. Dujovne CA, Zavoral JH, Rowe E, Mendel CM. Effects of sibutramine on body weight and serum lipids: A double-blind, randomized, placebocontrolled study in 322 overweight and obese patients with dyslipidemia. American heart journal 2001;142(3):489-497 (Pubitemid 32801634)
20. Erdmann J, Lippl F, Klose G, Schusdziarra V. Cholesterol lowering effect of dietary weight loss and orlistat treatment - Efficacy and limitations. Alimentary Pharmacology and Therapeutics 2004;19(11):1173-1179 (Pubitemid 38746260)
21. Fanghanel G, Cortinas L, Sanchez-Reyes L, Berber A. A clinical trial of the use of sibutramine for the treatment of patients suffering essential obesity. International Journal of Obesity & Related Metabolic Disorders: Journal of the International Association for the Study of Obesity 2000;24(2):144-150 (Pubitemid 30107561)
22. Fanghanel G, Cortinas L, Sanchez-Reyes L, Berber A. Second phase of a double-blind study clinical trial on Sibutramine for the treatment of patients suffering essential obesity: 6months after treatment cross-over. International Journal of Obesity & Related Metabolic Disorders: Journal of the International Association for the Study of Obesity 2001;25(5):741-747 (Pubitemid 32417646)
23. Finer N, James WP, Kopelman PG, Lean ME, Williams G. Oneyear treatment of obesity: a randomized, double-blind, placebo-controlled, multicentre study of orlistat, a gastrointestinal lipase inhibitor. International Journal of Obesity & Related Metabolic Disorders: Journal of the International Association for the Study of Obesity 2000;24(3):306-313 (Pubitemid 30137720)
24. Fujioka K, Seaton TB, Rowe E, Jelinek CA, Raskin P, Lebovitz HE, et al.Weight loss with sibutramine improves glycaemic control and other metabolic parameters in obese patients with type 2 diabetes mellitus. Diabetes, Obesity & Metabolism 2000;2(3):175-187 (Pubitemid 33072186)
25. Gentile S, Guarina G, Padovano B, Buonocunto F, Gruppo Campano Obesita. Efficacy and safety of a short-time orlistat treatment in obese subjects]. Italian]. Annali Italiani di Medicina Interna 2005;20(2):90-96
26. Ginsberg DL. Add-on sibutramine for olanzapine-induced weight gain. Primary Psychiatry 2004;11(7):24.
27. Halpern A, Leite CC, Herszkowicz N, Barbato A, Costa AP. Evaluation of efficacy, reliability, and tolerability of sibutramine in obese patients, with an echocardiographic study. Revista do Hospital das Clinicas; Faculdade de Medicina Da Universidade de Sao Paulo 2002;57(3):98-102.
28. Halpern A, Mancini MC, Suplicy H, Zanella MT, Repetto G, Gross J, et al.Latin-American trial of orlistat for weight loss and improvement in glycaemic profile in obese diabetic patients. Diabetes, Obesity & Metabolism 2003;5(3):180-188 (Pubitemid 36519351)
29. Hauner H, Meier M, Wendland G, Kurscheid T, Lauterbach K, Study Group, et al.Weight reduction by sibutramine in obese subjects in primary care medicine: the SAT Study. Experimental & Clinical Endocrinology & Diabetes 2004;112(4):201-207 (Pubitemid 38639291)
30. Hauptman J, Lucas C, Boldrin MN, Collins H, Segal KR. Orlistat in the long-term treatment of obesity in primary care settings.see comment]. Archives of Family Medicine 2000;9(2):160-167 (Pubitemid 30706616)
31. Hollander P. Endocannabinoid blockade for improving glycemic control and lipids in patients with type 2 diabetes mellitus. American Journal of Medicine 2007;120(2 Suppl 1):S18-28. (Pubitemid 46216207)
32. Hung YJ, Chen YC, Pei D, Kuo SW, Hsieh CH, Wu LY, et al.Sibutramine improves insulin sensitivity without alteration of serum adiponectin in obese subjects with Type 2 diabetes. Diabetic Medicine 2005;22(8):1024-1030 (Pubitemid 41025999)
33. James WP, Avenell A, Broom J, Whitehead J. A one-year trial to assess the value of orlistat in the management of obesity. International Journal of Obesity & Related Metabolic Disorders: Journal of the International Association for the Study of Obesity 1997;21 Suppl 3:S24-30, 1997 Jun.:-30.
34. James WP, Astrup A, Finer N, Hilsted J, Kopelman P, Rossner S, et al.Effect of sibutramine on weight maintenance after weight loss: a randomised trial. STORM Study Group. Sibutramine Trial of Obesity Reduction and Maintenance.see comment]. Lancet 2000;356(9248):2119-2125
35. Kaukua JK, Pekkarinen TA, Rissanen AM. Health-related quality of life in a randomised placebo-controlled trial of sibutramine in obese patients with type II diabetes. International Journal of Obesity & Related Metabolic Disorders: Journal of the International Association for the Study of Obesity 2004;28(4):600-605
36. Kelley DE, Bray GA, Pi-Sunyer FX, Klein S, Hill J, Miles J, et al.Clinical efficacy of orlistat therapy in overweight and obese patients with insulin-treated type 2 diabetes: A 1-year randomized controlled trial.erratum appears in Diabetes Care. 2003 Mar;26(3):971.]. Diabetes Care 2002;25(6):1033-1041 (Pubitemid 36929390)
37. Lindgarde F. The effect of orlistat on body weight and coronary heart disease risk profile in obese patients: the Swedish Multimorbidity Study.see comment]. Journal of Internal Medicine 2000;248(3):245-254 (Pubitemid 30693796)
38. Lindgarde F. Orlistat with diet was effective and safe for weight loss and coronary risk reduction in obesity. Evidence-Based Medicine 2001;6(2):54. (Pubitemid 33100816)
39. Lindgarde F. Effect of orlistat on coronary heart disease risk in obese patients with hypertension and/or hyperlipidemia. Am Heart J 2001;141(1):171.
40. McNulty SJ, Ur E, Williams G, Multicenter Sibutramine Study Group. A randomized trial of sibutramine in the management of obese type 2 diabetic patients treated with metformin. Diabetes Care 2003;26(1):125-131
41. Miles JM, Leiter L, Hollander P, Wadden T, Anderson JW, Doyle M, et al.Effect of orlistat in overweight and obese patients with type 2 diabetes treated with metformin.erratum appears in Diabetes Care. 2002 Sep;25(9):1671.]. Diabetes Care 2002;25(7):1123-1128 (Pubitemid 41071130)
42. Pathan MF, Latif ZA, Nazneen NE, Mili SU. Orlistat as an adjunct therapy in type 2 obese diabetic patients treated with sulphonylurea: a Bangladesh experience. Bangladesh Medical Research Council Bulletin 2004;30(1):1-8.
43. Patschan S, Scholze J. Obesity-related hypertension. Cardiology Review 2007;24(12):32-35
44. Pi-Sunyer FX, Aronne LJ, Heshmati HM, Devin J, Rosenstock J, RIO-North America Study Group. Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial.see comment]erratum appears in JAMA. 2006 Mar 15;295(11):1252]. JAMA 2006;295(7):761-775
45. Reaven G, Segal K, Hauptman J, Boldrin M, Lucas C. Effect of orlistat-assisted weight loss in decreasing coronary heart disease risk in patients with syndrome X. American Journal of Cardiology 2001;87(7):827-831 (Pubitemid 32244199)
46. Rossner S, Sjostrom L, Noack R, Meinders AE, Noseda G. Weight loss, weight maintenance, and improved cardiovascular risk factors after 2 years treatment with orlistat for obesity. European Orlistat Obesity Study Group. Obesity Research 2000;8(1):49-61.
47. Rossner S. Sibutramine - antidepressive agent tested against obesity. [Swedish]. Lakartidningen 2001;98(15):1802-1803
48. Samuelsson L, Gottsater A, Lindgarde F. Decreasing levels of tumour necrosis factor alpha and interleukin 6 during lowering of body mass index with orlistat or placebo in obese subjects with cardiovascular risk factors. Diabetes, Obesity and Metabolism 2003;5(3):195-201. (Pubitemid 36519353)
49. Scheen AJ, Ernest P. New antiobesity agents in type 2 diabetes: Overview of clinical trials with sibutramine and orlistat. Diabetes and Metabolism 2002;28(6 I):437-445 (Pubitemid 36077145)
50. Sjostrom L, Rissanen A, Andersen T, Boldrin M, Golay A, Koppeschaar HP, et al.Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. European Multicentre Orlistat Study Group.see comment]. Lancet 1998;352(9123):167-172
51. Swinburn BA, Carey D, Hills AP, Hooper M, Marks S, Proietto J, et al.Effect of orlistat on cardiovascular disease risk in obese adults. Diabetes, Obesity & Metabolism 2005;7(3):254-262 (Pubitemid 40542816)
52. Tambascia MA, Geloneze B, Repetto EM, Geloneze SR, Picolo M, Magro DO. Sibutramine enhances insulin sensitivity ameliorating metabolic parameters in a double-blind, randomized, placebo-controlled trial. Diabetes, Obesity & Metabolism 2003;5(5):338-344 (Pubitemid 37138865)
53. Tiikkainen M, Bergholm R, Rissanen A, Aro A, Salminen I, Tamminen M, et al.Effects of equal weight loss with orlistat and placebo on body fat and serum fatty acid composition and insulin resistance in obese women. American Journal of Clinical Nutrition 2004;79(1):22-30. (Pubitemid 41132058)
54. Van Gaal LF, Rissanen AM, Scheen AJ, Ziegler O, Rossner S, RIO-Europe Study Group. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study.see comment]erratum appears in Lancet. 2005 Jul 30-Aug 5;366(9483):370]. Lancet 2005;365(9468):1389-1397 (Pubitemid 40523733)
55. Van Gaal LF, Scheen AJ, Rissanen AM, Rossner S, Hanotin C, Ziegler O, et al.Long-term effect of CB1 blockade with rimonabant on cardiometabolic risk factors: two year results from the RIO-Europe Study. European Heart Journal 2008;29(14):1761-1771 (Pubitemid 352019811)
56. Wirth A, Krause J. Long-term weight loss with sibutramine: a randomized controlled trial.see comment]. JAMA 2001;286(11):1331-1339 (Pubitemid 33015524)
57. Zannad F, Gille B, Grentzinger A, Bruntz JF, Hammadi M, Boivin JM, et al.Effects of sibutramine on ventricular dimensions and heart valves in obese patients during weight reduction. American heart journal 2002;144(3):508-515 (Pubitemid 35052897)
58. Zavoral JH. Treatment with orlistat reduces cardiovascular risk in obese patients. Journal of Hypertension 1998;16(12 Pt 2):2013-2017
59. Aucott L, Poobalan A, Smith WC, Avenell A, Jung R, Broom J. Effects of weight loss in overweight/obese individuals and long-term hypertension outcomes: a systematic review. Hypertension 2005;45(6):1035-1041 [PUBMED: 15897373] (Pubitemid 40770300)
60. Canadian Hypertension Education Program (CHEP). Recommendations for the Management of Hypertension. [updated 2008; cited 2008 Aug 6]. Available from: http://hypertension.ca/chep/wp-content/uploads/2008/03/2008-chepspiral-booklet- final-jan28.pdf. Canadian Hypertension Education Program (CHEP).
61. The Cochrane Collaboration. Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.0 [updated 2008 Feb; cited 2008 Aug 6]. Available from: http://www.cochrane-handbook.org/. Chichester, UK: John Wiley & Sons, Ltd.
62. U.S. National Institutes of Health [homepage on the Internet]. Comprehensive Rimonabant Evaluation Study of Cardiovascular ENDpoints and Outcomes (CRESCENDO). 2008 [updated 2008 Apr 25; cited 2008 Aug 6]. Available from: http://www.clinicaltrials.gov/ct2/show/NCT00263042. U.S. National Institutes of Health.
63. Derosa G, Cicero AF, Murdolo G, Piccinni MN, Fogari E, Bertone G, et al.Efficacy and safety comparative evaluation of orlistat and sibutramine treatment in hypertensive obese patients. Diabetes, obesity & metabolism 2005;7(1):47-55. [PUBMED: 15642075]
64. Despres JP, Golay A, Sjostrom L. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. The New England journal of medicine 2005;353(20):2121-2134 [PUBMED: 16291982] (Pubitemid 41653104)
65. European Medicines Agency. Questions and answers on the recommendation to suspend the marketing authorisation of Acomplia (rimonabant) [updated 2008 Oct 23; cited 2009 Mar 17]. Available from: http://www.emea.europa.eu/humandocs/ PDFs/EPAR/acomplia/53715308en.pdf. European Medicines Agency, Post-authorisation Evaluation of Medicines for Human Use.
66. European Medicines Agency. The European Medicines Agency recommends suspension of the marketing authorisation of Acomplia [updated 2008 Oct 23; cited 2009 Mar 17]. Available from: http://www.emea.europa.eu/humandocs/PDFs/ EPAR/acomplia/53777708en.pdf. European Medicines Agency, Press office.
67. European Medicines Agency. Public statement on Acomplia (rimonabant). Withdrawal of the marketing authorisation in the European Union [updated 2009 Jan 30; cited 2009 Mar 17]. Available from: http://www.emea.europa.eu/humandocs/ PDFs/EPAR/acomplia/3945709en.pdf. European Medicines Agency, Post-authorisation Evaluation of Medicines for Human Use.
68. Mancia G, De BG, Dominiczak A, Cifkova R, Fagard R, Germano G, et al.2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007;25(6):1105-1187 [PUBMED: 17563527] (Pubitemid 46924065)
69. Food, Drug Administration. Egan AG. Colman EG. FDA Rimonabant Briefing Document. Endocrine and Metabolic Drugs Advisory Committee. 2007 [updated 2007 Jun 13; cited 2008 Aug 6]. Available from: http://www.fda.gov/ohrms/dockets/AC/ 07/briefing/2007-4306b1-fda-backgrounder.pdf. Food and Drug Administration, Endocrine and Metabolic Drugs Advisory Committee.
70. Horvath K, Jeitler K, Siering U, Stich AK, Skipka G, Gratzer TW, et al.Long-termeffects of weight-reducing interventions in hypertensive patients: systematic review and meta-analysis. Archives of internal medicine 2008;168(6):571-580 [PUBMED: 18362248]
71. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG). Evaluation of the benefits and harms of non-drug weight-reducing treatment strategies in patients with essential hypertension [Nutzenbewertung nichtmedikamentöser Behandlungsstrategien bei Patienten mit Bluthochdruck: A-Gewichtsreduktion]. http://iqwig.de/download/A05-21A- Abschlussbericht-Gewichtsreduktion-bei-Bluthochdruck-neu.pdf. Köln: Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG), 2006:19-119.
72. James W Philip T. The SCOUT study: risk-benefit profile of sibutramine in overweight high-risk cardiovascular patients. European Heart Journal Supplements 2005;7(suppl-L):L44-48.
73. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL, et al.The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003;289(19):2560-2572 [PUBMED: 12748199]
74. Kim SH, Lee YM, Jee SH, Nam CM. Effect of sibutramine on weight loss and blood pressure: a meta-analysis of controlled trials. Obesity Research 2003;11(9):1116-1123 [PUBMED: 12972682]
75. National Institute for Health and Clinical Excellence. Essential hypertension: managing adult patients in primary care. North of England Hypertension Guideline Development Group. 2004 [updated 2006 Jun; cited 2008 Aug 6]. Available from: http://www.nice.org.uk/nicemedia/pdf/CG18background.pdf. Newcastle: National Institute for Health and Clinical Excellence, North of England Hypertension Guideline Development Group.
76. Padwal RS, Majumdar SR. Drug treatments for obesity: orlistat, sibutramine, and rimonabant. Lancet 2007;369(9555):71-77 [PUBMED: 17208644]
77. Pi-Sunyer FX, Aronne LJ, Heshmati HM, Devin J, Rosenstock J. Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial. JAMA : the journal of the American Medical Association 2006;295(7):761-775 [PUBMED: 16478899] (Pubitemid 43244304)
78. Rucker D, Padwal R, Li SK, Curioni C, Lau DC. Long term pharmacotherapy for obesity and overweight: updated meta-analysis. BMJ 2007;335(7631):1194-1199 [PUBMED: 18006966] (Pubitemid 350273303)
79. Scheen AJ, Finer N, Hollander P, Jensen MD, Van Gaal LF. Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study. Lancet 2006;368(9548):1660-1672 [PUBMED: 17098084] (Pubitemid 46048528)
80. U.S. National Institutes of Health [homepage on the Internet]. A Long Term Study of Sibutramine and the Role of Obesity Management in Relation to Cardiovascular Disease in Overweight and Obese Patients. (SCOUT). 2008 [updated 2008 Jul 11; cited 2008 Aug 6]. Available from: http://www.clinicaltrials.gov/ ct2/show/NCT00234832. U.S. National Institutes of Health.
81. Sharma AM, Caterson ID, Coutinho W, Finer N, Van Gaal L, Maggioni AP, et al.Blood pressure changes associated with sibutramine and weight management - an analysis from the 6-week lead-in period of the sibutramine cardiovascular outcomes trial (SCOUT). Diabetes, obesity & metabolism 2009;11(3):239-250 [PUBMED: 18671798]
82. Sjostrom L, Rissanen A, Andersen T, Boldrin M, Golay A, Koppeschaar HP, et al.Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. European Multicentre Orlistat Study Group. Lancet 1998;352(9123):167-172 [PUBMED: 9683204]
83. Van Gaal LF, Rissanen AM, Scheen AJ, Ziegler O, Rossner S. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet 2005;365(9468):1389-1397 [PUBMED: 15836887] (Pubitemid 40523733)
84. World Health Organization [homepage on the Internet]. The world health report 2002 - reducing risks, promoting healthy life. 2002 [cited 2008 Aug 6]. Available from: http://www.who.int/entity/whr/2002/en/whr02-en.pdf. WHO.
85. World Health Organization [homepage on the internet]. Khatib OMN, El-Guindy MS, editors. Clinical guidelines for the management of hypertension. WHO EMRO Technical publication series, 29. 2005 [cited 2008 Aug 6]. Regional Office for the Eastern Mediterranean. Available from: http://www.emro.who.int/ dsaf/dsa234.pdf. Cairo: World Health Organization. Regional Office for the Eastern Mediterranean.